Company / Total Assets
CytomX Therapeutics, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$151.6M
FY2025
5-year range
$120.5M / $339.4M
FY2021-FY2025
Trend
+25.7%
vs FY2024
Sector context
#204 of 214
Health Care
What the data says
Among 214 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 5% for total assets. Total Assets returned to growth in FY2025 after 4 years of decline, reaching $152M.
Based on SEC 10-K filings.
$152M in FY2025 with a 5-year CAGR of -15.8%.
Declined from $202M to $152M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -16.6%
- 5-Year CAGR
- -15.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 214This company $151.6M Sector average $7.5B
▼
-98.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -15.8%, indicating a declining trend.
- In FY2025, total assets increased 25.7% year-over-year.
- Ranks #204 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $151.6M | +25.7% |
| FY2024 | $120.5M | -40.3% |
| FY2023 | $201.8M | -22.7% |
| FY2022 | $260.9M | -23.1% |
| FY2021 | $339.4M | -5.4% |
| FY2020 | $358.7M | +5.1% |
| FY2019 | $341.3M | -25.3% |
| FY2018 | $457.1M | +15.0% |
| FY2017 | $397.6M | +99.7% |
| FY2016 | $199.1M | +1.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026